Yellow Fever Vaccination of Human Immunodeficiency Virus-Infected Patients: Report of 2 Cases

Receveur, M. C.; Thiébaut, Rodolphe; Védy, S.; Malvy, Denis; Mercié, P.; Bras, M. Le

doi:10.1086/314031

Cited by 65 publications

(31 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 In both patients, a decrease in CD4 cell count of approximately 200 occurred in the first month after vaccination without any disease manifestation and with a steady recovery. The retrospective study conducted by Tattevin and others also showed favorable efficacy results for a 17DYF vaccine in HIV-infected patients with CD4 cell counts 200 cells/mm 3 .…”

Section: Americanmentioning

confidence: 81%

See 1 more Smart Citation

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Society of Tropical Medicine and Hygiene

203

172

View full text Add to dashboard Cite

Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

show abstract

Section: Americanmentioning

confidence: 81%

“…Four retrospective observational studies reported a good immunologic response in HIV patients with CD4 cell counts 200 cells/mm 3 and variable viral load. [49][50][51][52] The seroconversion rates were high (92-100%) although the number of persons included in the analysis was small in three of the studies (2, 12, and 14 respectively).…”

Section: Americanmentioning

confidence: 97%

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Society of Tropical Medicine and Hygiene

203

172

View full text Add to dashboard Cite

show abstract

“…Pacanowski and others 37 reported on 103 patients at the Hô pital Saint Antoine, Paris, France. Receveur and others 38 reported two case reports from a travel clinic in Bordeaux, France. Tattevin and others 39 reported on 12 patients at Pontchaillou Hospital, Rennes, France.…”

Section: Resultsmentioning

confidence: 99%

The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review

Thomas¹,

Lorenzetti²,

Spragins³

et al. 2012

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Yellow fever vaccine provides long-lasting immunity. Rare serious adverse events after vaccination include neurologic or viscerotropic syndromes or anaphylaxis. We conducted a systematic review of adverse events associated with yellow fever vaccination in vulnerable populations. Nine electronic bibliographic databases and reference lists of included articles were searched. Electronic databases identified 2,415 abstracts for review, and 32 abstracts were included in this review. We identified nine studies of adverse events in infants and children, eight studies of adverse events in pregnant women, nine studies of adverse events in human immunodeficiency virus-positive patients, five studies of adverse events in persons 60 years and older, and one study of adverse events in individuals taking immunosuppressive medications. Two case studies of maternal-neonate transmission resulted in serious adverse events, and the five passive surveillance databases identified very small numbers of cases of yellow fever vaccine-associated viscerotropic disease, yellow fever vaccine-associated neurotropic disease, and anaphylaxis in persons ! 60 years. No other serious adverse events were identified in the other studies of vulnerable groups. BACKGROUND

show abstract

“…These include oral polio vaccine, vaccinia, bacillus Calmette-Guerin, and live oral typhoid (11). Although yellow fever vaccination has been used in case reports with human immunodeficiency virus infection (86), no data are available in solid-organ recipients. In our opinion the vaccine should be considered contraindicated.…”

Section: Live Vaccinesmentioning

confidence: 99%

Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols

Duchini¹,

Goss²,

et al. 2003

View full text Add to dashboard Cite

Recipients of solid-organ transplantation are at risk of severe infections due to their life-long immunosuppression. Despite emerging evidence that vaccinations are safe and effective among immunosuppressed patients, most vaccines are still underutilized in these patients. The efficacy, safety, and protocols of several vaccines in this patient population are poorly understood. Timing of vaccination appears to be critical because response to vaccinations is decreased in patients with end-stage organ disease and in the first 6 months after transplantation. For these reasons, the primary immunizations should be given before transplantation, as early as possible during the course of disease. Vaccination strategy should include vaccination of household contacts and health care workers at transplant centers unless contraindicated. No conclusive data are available on the use of immunoadjuvants and screening for protective titers. Most vaccines appear to be safe in solid-organ transplantation recipients, but live vaccines should be avoided until further studies are available. The risk of rejection appears minimal. Recommended vaccines include pneumovax, hepatitis A and B, influenza, and tetanus-diphtheria. We outline specific protocols and recommendations in this particular patient population. Specific contraindications exist for other vaccines, such as yellow fever, oral polio vaccine, bacillus Calmette-Guerin, and vaccinia. We conclude that solid-organ recipients will benefit from consistent immunization practices. Further studies are recommended to improve established protocols in this patient population

show abstract

Yellow Fever Vaccination of Human Immunodeficiency Virus-Infected Patients: Report of 2 Cases

Abstract: Yellow fever vaccine (17D, a live attenuated virus vaccine) was effective and safe in 2 human immunodeficiency virus-infected patients without severe immunosuppression, one of whom traveled to Kenya and the other of whom traveled to Senegal.

Cited by 65 publications

References 1 publication

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review

Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols

Contact Info

Product

Resources

About